Background: Tigecycline was approved for the treatment of complicated intra-abdominal and complicated skin/skin structure infections. Because of its in vitro effectiveness for multidrugresistant (MDR) isolates, tigecycline has been prescribed more broadly. This study evaluated tigecycline use after its first introduction in Taiwan and experience with tigecycline for the treatment of MDR Acinetobacter baumannii (MDRAB) infection, especially for ventilatorassociated pneumonia. Methods: Patients treated with tigecycline were collected retrospectively from February 2008 to July 2008 in Taipei Veterans General Hospital, a 2,900-bed tertiary care medical center in Taiwan. Patients were divided into three groups according to the indications: Group 1, Food and Drug Administrationeapproved indications; Group 2, health careeassociated pneumonia (HAP); and Group 3, urinary tract infection, osteomyelitis, bacteremia, etc. Cases of MDRAB were also identified. Results: Among 66 cases, indications for the administration of tigecycline included Food and Drug Administrationeapproved indications (12, 18 .2%), HAP (38, 57.6%), bacteremia (3, 4 .5%), catheter-related infections (3, 4.5%), urinary tract infection (4, 6.1%), osteomyelitis (4, 6.1%), and others (2, 3%). Clinical outcome was positive in 20 cases, with higher clinical success rate for Group 1 than Group 2, which may correlate with higher Sequential Organ Failure
Introduction
Tigecycline, the first of the glycylcyclines, was approved by the US Food and Drug Administration (FDA) for treatment of complicated intra-abdominal infection (cIAI) and complicated skin and skin structure infection (cSSSI). 1 Because of substitution of a N-alkyl-glycylamido group on the D ring at the ninth position, tigecycline can evade efflux pumps and ribosomal protection mechanisms associated with resistance to the tetracycline class and has a broader spectrum of activity. 1, 2 In addition to methicillin-resistant Staphylococcus aureus, tigecycline is also highly active in vitro against a variety of multidrug-resistant (MDR) clinical isolates, including glycopeptide-intermediate S aureus, penicillinresistant Streptococcus pneumoniae, vancomycin-resistant enterococci and extended-spectrum b-lactamaseeproducing Escherichia coli, and Klebsiella pneumoniae. 1, 3, 4 In vitro, it also showed bacteriostatic activity against Acinetobacter baumannii, an emerging cause of nosocomial infections. 5 With increasing frequency because of more vulnerable hosts and the ability to accumulate different mechanisms of resistance, A baumannii appears to be the species of greatest clinical importance. 6, 7 Multiple drug resistance to potentially effective antibiotics such as carbapenems, aminoglycosides, tetracyclines, fluoroquinolones, sulbactam, antipseudomonal penicillins, and broad-spectrum cephalosporins has been reported more frequently, mandating the introduction of combination therapy and novel antibiotics including glycylcyclines and polymyxins.
8e10 Favorable clinical outcomes of MDR A baumannii (MDRAB) treated with tigecycline have been reported in several studies, although rapidly emerging resistance and failure to eradicate A baumannii have also been reported. 4, 9, 11 Because the experience with tigecycline for treating MDRAB infections is never reported in Taiwan, we identified and analyzed data for cases treated with tigecycline after its first introduction, especially in treatment of critically ill and elderly patients with MDRAB infection.
Material and methods

Study design and patients
This retrospective review was conducted at the Taipei Veterans General Hospital, a 2,900-bed tertiary care medical center in Taiwan, from February 2008 to July 2008. All patients who received tigecycline for more than 72 hours regardless of infection type were identified. Age, sex, underlying diseases, admission settings (intensive care unit or general ward), indication for tigecycline use, Sequential Organ Failure Assessment (SOFA) score, and microbiological and clinical outcomes were documented. Previous and concomitant antimicrobial agents administered for more than 3 days were also recorded.
Patients were placed into one of three groups according to the indications for tigecycline use: Group 1, FDAapproved indications (cIAI and cSSSI); Group 2, health careeassociated pneumonia (HAP); and Group 3, urinary tract infection (UTI), osteomyelitis, bacteremia, or others.
HAP was defined as the presence of clinical symptoms and signs as well as radiographic evidence of pneumonia in patients who were hospitalized for more than 3 days, who were transferred from another health care facility or who had prior hospitalization within 30 days. Ventilator-associated pneumonia (VAP) was diagnosed by the presence of clinical symptoms and signs as well as radiographic evidence of pneumonia after initiation of mechanical ventilation. Bacteremia was defined as isolation of bacteria from blood culture, along with clinical symptoms and signs of systemic infection. UTI was diagnosed based on isolation of bacteria with concurrent pyuria. cSSSI was defined as infection requiring significant surgical intervention, involving deeper soft tissue, or accompanied by a significant underlying disease (diabetes mellitus, peripheral vascular disease, or lower extremity venous insufficiency) that complicates response to treatment. Sputum of adequate quality, lower respiratory tract secretions, or samples from sterile sites was sent for culture. Identification of bacteria was determined by phenotypic methods. All patients received a 100-mg loading dose followed by a 50-mg twice-daily maintenance dose. We also analyzed the subgroup infections of MDRAB. MDRAB was defined as any A baumannii isolate not sensitive to three or more antimicrobial classes including carbapenems, aminoglycosides, fluoroquinolones, sulbactam, antipseudomonal penicillins, and broad-spectrum cephalosporins, whereas extensive drug resistance (XDR) was defined as any microorganism not susceptible to any of the abovementioned antimicrobial agents. Concurrent antibiotics directed against A baumannii were recorded if administered for more than 72 hours.
Clinical outcome
Clinical cure was defined as resolution of signs and symptoms of infection and no further antibiotics administered for 3 days after the discontinuation of tigecycline. Continued presence of symptoms and signs of the infection that mandated discontinuation of tigecycline and addition of other antibiotic therapy, or death, was considered clinical failure.
Microbiological outcome
Cases that showed clinical success were followed for 1 week. Microbiological eradication was defined as negative culture in repeat cultures or clinical cure making a repeat culture unnecessary. Different isolates from any site or the same pathogen from a different site with concurrent symptoms and signs of infection was considered new infection. The same isolate from the original site was considered recurrence.
All subjects with clinical failure were also followed for 1 week. Presence of the baseline isolate in the repeat cultures from the original site or no culture data being available after clinical failure was considered persistence. Superinfection was defined as a new isolate obtained during the treatment of the original infection with development of symptoms and signs of clinical infection.
Data analysis
Qualitative variables were compared by the Pearson chisquared or Fisher exact test, and quantitative variables were compared by Kruskal-Wallis one-way test. For all analyses, a p value of <0.05 was considered significant for two-tailed tests.
Results
A total of 100 instances of tigecycline therapy at our institution were identified for the study period beginning with drug introduction in Taiwan. Thirty-four episodes were excluded because of duration of less than 72 hours or incomplete data collection. Sixty-five different patients with 66 episodes of tigecycline use were analyzed in this study. One patient had two episodes of infection including cIAI and HAP. Both were treated with tigecycline and referred as two episodes.
Antibiotic use for FDA-approved indications accounted for 12 cases (18.2%). Most cases (54/66, 81.8%) received tigecycline for off-label indications, including HAP (38, 57.6%), bacteremia (3, 4.5%), catheter-related infection (3, 4.5%), UTI (4, 6.1%), osteomyelitis (4, 6.1%), and others (2, 3%). Mean age of the 65 patients was 74.2 AE 16.1 years. Patients with Group 2 indications were older than those with Group 1 indications (78 years vs. 65 years, p < 0.05). Median duration of hospital stay was 49 days (range 8e533) without significant differences among the three groups (p Z 0.359). Fifty cases (75.8%) were male. Forty-seven patients (71.2%) were admitted to a medical service, whereas 38 patients (57.6%) received tigecycline in the intensive care unit. There were no significant differences between the three groups regarding proportion with medical ward admission (p Z 0.087). The proportion of patients who had intensive care unit stays during tigecycline treatment was higher among patients with Group 2 indications than those with Group 1 or Group 3 indications (76.3% vs. 16.7% and 43.8%, respectively, p < 0.05). The average SOFA score was 7.1 AE 5.1. Patients with Group 2 indications had higher SOFA score than those with Group 1 (8.6 vs. 2.8, p < 0.05). Median duration of tigecycline therapy and hospitalization before tigecycline use were 12 days (range 3e77) and 24 days (range 0e445), respectively, without significant differences among the three groups (p Z 0.46 and 0.1).
Only two cases did not receive antibiotics before tigecycline therapy. There were no significant differences among the three groups about the portion of patients with previous antibiotic therapy (p Z 0.67). Combination therapy was used in 43 cases. Patients with Group 2 indications had concurrent antibiotic treatment more frequently than those with Group 1 (73.7% vs. 25%, respectively, p < 0.05). Among 66 total episodes of tigecycline use, 51 pathogens were identified. The most commonly isolated organism was A baumannii (34/51, 66.7%). MDRAB was identified in 33 cases and more commonly isolated in Group 2 indications than Group 1 or Group 3 (65.8% vs. 25.0% and 31.3%, respectively, p < 0.05). XDR A baumannii (XDRAB) was identified in 16 patients (31.4%). There were 14 patients with polymicrobial infections. The majority (11/14, 78.6%) had Group 2 indications. Methicillin-resistant S aureus was the most common concurrent pathogens (7/14, 50%). Two patients had concurrent candidal infections, and both had unfavorable clinical outcomes. Other pathogens included K pneumoniae (including one with extended-spectrum b-lactamase), Citrobacter spp, Serratia spp, and Stenotrophomonas maltophilia. One patient with coexisting Pseudomonas aeruginosa infection was concurrently treated with ceftazidime, and one with Providencia stuartii infection was treated with cefepime.
Details of clinical outcomes and microbiological eradications are listed in infection, 15 had superinfection, and one could not be defined because resolution of fever was not achieved by empirical use of tigecycline for fever of unknown origin.
MDRAB infections
Eight patients with pneumonia but without ventilator use were excluded because patients of this type were not widely discussed in most previous studies. 9 We identified 25 patients who received tigecycline for the treatment of MDRAB infection. Eighteen patients (72%) received tigecycline for the treatment of VAP, three (12%) for cSSSI, three (12%) for bacteremia (including one case of catheterrelated bacteremia), and one (4%) for UTI. These patients had a mean age of 78.4 AE 12.4 years and median length of stay of 53 days (range 9e175). The average of SOFA score was 9.5 AE 4.5. Nearly all of patients (24/25, 96%) received mechanical ventilation during tigecycline treatment. Median duration of hospitalization before initiation of tigecycline was 21 days (range 2e74), and median treatment duration was 9.5 days (range 3e27). Polymicrobial infections were identified in eight patients (32%) and not associated with worse clinical outcomes (p Z 1.00). XDRAB was identified in 13 patients (52%). Among patients with VAP, the average age was 79.3 AE 12.7 years and the mean SOFA score was 9.9 AE 4.2.
Ten patients were treated with tigecycline monotherapy and 15 with combination therapy. Single combination therapy was used in 13 cases, including sulbactam (6/25, 24%), piperacillin/tazobactam (2/25, 8%), cefepime (3/25, 12%), and imipenem (2/25, 8%). Two patients received combination therapy consisting of one regimen after another, one receiving ceftazidime followed by aztreonam and the other receiving piperacillin/tazobactam followed by imipenem þ sulbactam. The sole patient with successful clinical and microbiological outcomes was treated with tigecycline and imipenem. One patient experienced thrombocytopenia (148,000e48,000/mL); no other adverse events were reported.
Clinical and microbiological outcomes are listed in Table 2 . Clinical success was achieved in only three (12%) patients. Microbiological eradication was seen in one case, and new infections (Burkholderia cepacia bacteremia and P aeruginosa urosepsis) were identified in the others. Tigecycline failed clinically in 22 patients (88%), consisting of 18 persistent infections and four superinfections. Two cases with pneumonia developed bacteremia, one with Chryseobacterium meningosepticum and one with Chryseobacterium indologenes. Seventeen (68%) patients did not survive to discharge.
Discussion
In the present study, we demonstrated the effectiveness of tigecycline in clinical practice after its first introduction. However, because of the retrospective nature, susceptibility result of tigecycline was not available. The 18.2% use of tigecycline for FDA-approved indications may be explained by availability of other effective therapeutic options for cSSSI and cIAI. 12 Tigecycline was an alternative antimicrobial agent for cIAI in Taiwan. 13 Most cases (81.8%) received tigecycline for off-label use, especially for HAP (57.6%). Similarly in Argentina, 78% of the tigecycline prescriptions were for off-label use during its first month of commercial use, especially for VAP (61%) due to MDR Acinetobacter spp infection. 14 In our study, cases with HAP were older (mean age 78 years), were more frequently admitted to the intensive care unit (76.3%), and had higher SOFA score (mean 8.6). Prior antibiotic use was found in almost all cases. Furthermore, MDRAB was more common (65.8%) in patients with Group 2 indications. In such severely ill patients who had experienced multiple antibiotics and infected by MDRAB, therapeutic options were relatively limited and mortality was high. 8, 10, 11, 15, 16 Although new agents as well as new strategies and reintroduction of antibiotics have been developed, most of the clinical studies were of small sizes and not randomized. 5, [8] [9] [10] Because no comparative trial was conducted, tigecycline is one of the drug choices for such critically ill patients. 4, 5, 9, 11 That may also be the reason why concurrent antibiotics were used more frequently in patients with the Group 2 indications.
The overall clinical success rate in our study was 30.3%. The clinical success rate was significantly higher for FDAapproved indications than for HAP (66.7% vs. 18.4%). Among cases infected with MDRAB, the clinical success rate was only 12%, and for VAP caused by MDRAB, the success rate was 5.6% (1/18), a finding that was quite different from the results of other studies. 4, 9, 11, 14 Anthony et al. 4 reported a clinical success rate of 50% (5/10) for serious infections with A baumannii. Schafer et al. 11 also reported 84% (21/ 25) of patients with VAP and/or bacteremia caused by MDRAB had clinical resolution. The overall clinical success in 86 of the 113 (76.1%) patients treated with tigecycline after its first commercialization in Argentina was reported, whereas clinical success rate in patients with VAP caused by MDRAB was 64% (32/50).
14 However, one study showed unfavorable clinical outcome (28%) in patients with pneumonia, bacteremia, and UTI caused by Acinetobacter spp. 17 The poor outcomes in our study may be because of multiple factors. Not only with many comorbidities and ventilator use, our patients were also critically ill and aged. The length of overall hospitalization and duration before tigecycline administration were long, implying serious underlying conditions in our patients. In addition, the definition of clinical success in our study was stricter. The clinical success rate increased to 28% (7/25 for MDRAB infections) and 22.2% (4/18 for VAP), if the change of antibiotics was because of persistence of previous infection but not superinfections, as previous studies described. 4, 11, 14 The XDRAB rate was also high (13/25, 52%) in our series, which may cause adverse impacts on the clinical consequences because of inappropriate therapy. 18 It is difficult to analyze all factors associated with clinical outcomes because of relatively small number of patients and diversity of underlying diseases.
Although some clinical studies had positive findings, 4, 17 the clinical outcomes of one episode of UTI, two episodes of bacteremia, and one episode of catheter-related bacteremia because of MDRAB were all poor in our study. Tigecycline is mainly excreted through the gastrointestinal tract, with less than 15% of an administered dose excreted unchanged in the urine and serum concentration is also suboptimal for antibacterial activity. 19, 20 It has been reported that bloodstream infections were caused by tigecycline-nonsusceptible A baumannii in patients receiving tigecycline for other indications. 21 The use of tigecycline for treating UTI and bloodstream infections should be more cautious. 4 Several patients in the present study had bacteremia or UTI caused by C indologenes, XDRAB, or vancomycin-resistant enterococci.
Although tigecycline is in vitro and in vivo active against many MDR organisms, it has limited activity against P aeruginosa, indole-positive Proteae, and Proteus mirabilis.
1 Of our cases with clinical success, two developed new infections, one with B cepacia bacteremia and one with Pseudomonas urosepsis, after tigecycline use. Of cases with microbiological failure, one with bacteremia of C meningosepticum and one with C indologenes were found. Superinfection with tigecycline-nonsusceptible A baumannii during tigecycline use for other indications has been reported, but superinfection with other strains has not been reported. 21 The most common side effects of tigecycline including nausea and vomiting in a previous study 22 could not be accessed in most of our patients because they either had old cerebrovascular diseases or were intubated. There was no documented serious adverse effect associated with tigecycline use except thrombocytopenia in one patient.
In conclusion, the most common indication for tigecycline prescription was not cIAI or cSSSI but HAP in our institution. The success rate was higher for FDA-approved indications than that for HAP. Although the success rate with tigecycline was not as effective as previous studies reported, serious underlying conditions and comorbidities in our patients may be the culprit. In view of limited drug choices and high mortality in such critically ill and aged patients with infection caused by MDRAB, tigecycline may be one of the alternative choices.
